Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 5 studies | 26% ± 4% | |
enterocyte | 4 studies | 20% ± 4% | |
erythrocyte | 4 studies | 24% ± 3% | |
platelet | 3 studies | 31% ± 6% | |
cardiac muscle cell | 3 studies | 24% ± 3% |
Insufficient scRNA-seq data for expression of ANKRD9 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2504.39 | 245 / 245 | 100% | 12.38 | 500 / 502 |
esophagus | 100% | 2292.61 | 1444 / 1445 | 99% | 20.64 | 182 / 183 |
intestine | 100% | 3856.98 | 964 / 966 | 99% | 19.24 | 522 / 527 |
stomach | 100% | 2282.84 | 358 / 359 | 98% | 17.86 | 280 / 286 |
bladder | 100% | 1572.05 | 21 / 21 | 97% | 14.73 | 489 / 504 |
ovary | 98% | 1250.64 | 176 / 180 | 97% | 12.00 | 419 / 430 |
brain | 99% | 2640.54 | 2620 / 2642 | 95% | 11.03 | 669 / 705 |
lung | 98% | 1844.84 | 565 / 578 | 94% | 10.73 | 1090 / 1155 |
breast | 97% | 1241.78 | 444 / 459 | 94% | 9.65 | 1052 / 1118 |
uterus | 91% | 834.00 | 155 / 170 | 98% | 18.68 | 450 / 459 |
skin | 92% | 1961.81 | 1661 / 1809 | 97% | 14.92 | 457 / 472 |
kidney | 100% | 2636.35 | 89 / 89 | 88% | 10.94 | 794 / 901 |
adrenal gland | 100% | 1794.95 | 257 / 258 | 84% | 8.06 | 193 / 230 |
pancreas | 84% | 739.03 | 276 / 328 | 98% | 10.79 | 174 / 178 |
thymus | 100% | 1838.59 | 650 / 653 | 78% | 5.55 | 473 / 605 |
liver | 80% | 815.30 | 181 / 226 | 83% | 6.56 | 339 / 406 |
muscle | 100% | 9015.17 | 803 / 803 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 12.25 | 1 / 1 |
heart | 100% | 6056.55 | 857 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 25.85 | 79 / 80 |
spleen | 98% | 1025.32 | 236 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 16.45 | 43 / 45 |
adipose | 95% | 1132.25 | 1138 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 88% | 931.32 | 1176 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 59% | 744.69 | 544 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.35 | 2 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006878 | Biological process | intracellular copper ion homeostasis |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0031466 | Cellular component | Cul5-RING ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_0031410 | Cellular component | cytoplasmic vesicle |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
Gene name | ANKRD9 |
Protein name | Ankyrin repeat domain-containing protein 9 Ankyrin repeat domain 9 |
Synonyms | |
Description | FUNCTION: Substrate receptor subunit of a cullin-RING superfamily E3 ligase complex (CUL5-based E3 ubiquitin ligase complex) which mediates the ubiquitination and subsequent proteasomal degradation of target proteins . Depending of the metabolic state of the cell, promotes the proteasomal degradation of IMPDH2, the rate-limiting enzyme in GTP biosynthesis or protects IMPDH2 by stabilizing IMPDH2 filaments assembly . Implicated in different cellular processes, like copper homeostasis and cell proliferation . . |
Accessions | ENST00000559651.1 H0YM08 Q96BM1 H0YNN1 ENST00000557902.1 ENST00000560748.5 ENST00000559404.5 ENST00000286918.9 |